Neoadjuvant hormones: 8-months regimen appears to be no better than3-month regimen

Eight months of neoadjuvant hormone therapy prior to radiation therapyappears to offer no significant advantage over the standard of 3 monthsof therapy, at least in low- and intermediate-risk prostate cancer patients.